



GP73-regulated oncolytic adenoviruses possess potent killing effect on human liver cancer stem-like cells

Supplementary Materials




Supplementary Figure S1: The attributes of differentiation for PLC/PRF/5 sphere cells. (A) PLC/PRF/5 sphere cells differentiated to their parental counterparts through culturing adherently in 10% FBS medium by 7 days. scale bar: 200 μ m. (B) PLC/PRF/5 sphere cells differentiated by 4 days in 5% FBS medium adherently still elevated liver CSCs-associated genes. All experiments were repeated three times and all data shown represented mean \pm SD ($n = 3$). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.




Supplementary Figure S2: PLC/PRF/5 sphere cells upregulated the related genes and proteins associated with CSCs.

(A) Western blot indicated that sphere cells activated PI3K/AKT signaling pathway and increased phosphorylation levels of STAT3 than parental cells in PLC/PRF/5. (B) PLC/PRF/5 sphere cells overexpressed the epithelial-mesenchymal transition-inducing markers (e.g., Fibronectin and N-Cadherin) and transcription factors (e.g., Twist and Slug) when compared to PLC/PRF/5 cells. qRT-PCR data were normalized to GAPDH gene and shown as fold change relative to PLC/PRF/5 cells. (C) Upregulation of the related mRNAs of drug-resistance (e.g., ABCG2, MDR1, MRP1) in PLC/PRF/5 sphere cells. qRT-PCR data were normalized to GAPDH gene and are shown as fold change relative to PLC/PRF/5 cells. (D) DR5 (dopamine receptors 5) protein level increased in PLC/PRF/5 sphere cells. All experiments were repeated three times and all data shown represented mean \pm SD ($n = 3$). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.



Supplementary Figure S3: Cell cycle distribution of PLC/PRF/5 cells and PLC/PRF/5 sphere cells. Numbers indicate the proportion of G0/G1 phase cells.



Supplementary Figure S4: Construction of adenoviruses and cytotoxic effect of GD55 on PLC/PRF/5 sphere cells.

(A) PLC/PRF/5 sphere cells acquired a little more expression level of GP73 when compared to PLC/PRF/5 cells. qRT-PCR data were normalized to GAPDH gene and shown as fold change relative to PLC/PRF/5 cells. (B) Schematic structure of recombinant oncolytic adenovirus was compared to the wild type adenovirus (Ad5WT). GD55 was designed with E1A promoter replaced by *GOLPH2* core promoter and E1B 55 kDa gene deletion. (C) Morphological observation of PLC/PRF/5 sphere cells after treated with ZD55 and GD55 (5MOI) for 72 h. scale bar: 200 μ m. (D) PLC/PRF/5 sphere cells were infected with GD55 or ZD55 at a MOI of 5. On the day 1, 2, 3, and 4 postinfection, cell viability was measured with MTT assay. All experiments were repeated three times and all data shown represented mean \pm SD ($n = 3$). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

Supplementary Table S1: Sequences of Primers

Primers	Sequences
Nanog-forward	5'- CTCTCCTCTTCCTTCCTCCAT-3'
Nanog-reverse	5'- TTGCGACACTCTTCTCTGC-3'
Oct4-forward	5'- CTTGCTGCAGAAGTGGGTGGAGGAA -3'
Oct4-reverse	5'- CTGCAGTGTGGGTTTCGGGCA-3'
Sox2-forward	5'- AAATGGGAGGGGTGCAAAAGAGGAG -3'
Sox2-reverse	5'- CAG CTG TCA TTT GCT GTG GGT GAT G-3'
CD44-forward	5'- CGGACACCATGGACAAGTTT-3'
CD44-reverse	5'- GAAAGCCTTGCAGAGGTCAG-3'
CD90-forward	5'- GACCCGTGAGACAAAGAAGC-3'
CD90-reverse	5'- GCCCTCACACTTGACCAGTT-3'
Albumin-forward	5'- CACAAAGATGACAACCCAAACCTCC-3'
Albumin-reverse	5'- GGAGTTCCGGGGCATAAAAGTAAG-3'
GAPDH-forward	5'-GATTTGGTCGTATTGGGCG-3'
GAPDH-reverse	5'-TGGAAGATGGTGTATGGGAT-3'
c-Myc-forward	5'- GCACTGGAAGTTACAACAC-3'
c-Myc-reverse	5'- GGAGAGCCTTTCAGAGAAG-3'
CD133-forward	5'-AAGCATTGGCATCTTCTATGG-3'
CD133-reverse	5'-AAGCACAGAGGGTCATTGAGA-3'
EpCAM-forward	5'-GCGGCTCAGAGAGACTGTG -3'
EpCAM-reverse	5'-CCAAGCATTTAGACGCCAGTTT-3'
CD24-forward	5'-TGAAGAACATGTGAGAGGTTTGAC-3'
CD24-reverse	5'-GAAAACCTGAATCTCCATTCCACAA-3'
ABCG2-forward	5'- GTTCTCAGCAGCTCTTCGGCTT -3'
ABCG2-reverse	5'- TCCTCCAGACACACCACGGATA -3'
MDR1-forward	5'- CATTGGTGTGGTGAGTCAG -3'
MDR1-reverse	5'- GTCATAGGCATTGGCTTCC -3'
MRP1-forward	5'-AAGACCAAGACGTATCAGGT-3'
MRP1-reverse	5'-CAATGGTCACGTAGACGGCAA-3'
Fibronectin-forward	5'- CAGTGGGAGACCTCGAGAAG -3'
Fibronectin-reverse	5'- TCCCTCGGAACATCAGAAAC -3'

N-Cadherin-forward	5'- ACAGTGGCCACCTACAAAGG-3'
N-Cadherin -reverse	5'- CCGAGATGGGGTTGATAATG-3'
G6P-forward	5'-GTCTGTCACGAATCTACCTTG-3'
G6P-reverse	5'-CTACACCCAGTCCCTTGAG-3'
Twist-forward	5'-AAGGCATCACTATGGACTTTCTCT-3'
Twist-reverse	5'-GCCAGTTTGATCCCAGTATTTT-3'
Slug-forward	5'-GCATTTCTTCACTCCGAAGC-3'
Slug-reverse	5'-TGAATTCCATGCTCTTGCAG-3'
GP73-forward	5'-GTGTGAGGAGCGAATAGAAGAGG-3'
GP73-reverse	5'-GTCTCTGGTCGTTGTTTTCACT-3'